Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

The conversation discusses the effectiveness and value of a Locklabs pill containing finasteride, minoxidil, biotin, and a low dose of dutasteride for hair loss. The user is uncertain if the .1mg dutasteride dosage is sufficient and worth the cost.

The user experienced regrowth and stabilization in hair density using finasteride, minoxidil, a derma roller, and an LLLT helmet, but noticed a recent decline in hair quality. They only take finasteride orally and are unsure about the effectiveness of the LLLT device.

PP405 is a new hair loss treatment in phase 2 trials that may promote hair growth by increasing lactate production and activating hair follicle stem cells. It could potentially replace hormone-disrupting treatments like Minoxidil and finasteride.

Longitudinal partial follicular unit transplantation involves extracting part of the donor follicular unit, allowing the donor area to be overharvested without noticeable hair loss. The conversation questions if this method is practiced in clinics or if it's theoretical, and whether it relates to hair cloning or multiplication.

FLEAVA is accused of scamming customers by enrolling them in unwanted monthly subscriptions for Advanced Copper Peptide without consent. Many users struggled to get refunds and reported ongoing charges despite cancellation requests.

The conversation discusses using P5P (Vitamin B6) supplements to reduce elevated Prolactin levels and concerns about its potential effect on increasing DHT levels. The user is not currently using finasteride or any anti-androgens.

Low Dose Naltrexone (LDN) may reduce inflammation in alopecia conditions. It is discussed as a potential adjunct treatment with finasteride or dutasteride for androgenic alopecia.

The user experienced hair loss possibly due to scalp damage and tried natural treatments with limited success. They reported noticeable hair thickening after using a laser treatment device, suggesting it may be effective, especially for those on finasteride.

AMP-303 and AMP-601 are new hair loss treatments targeting dermal papilla cells, with AMP-303 showing early efficacy in transitioning vellus hairs to terminal hairs after one injection. Further clinical trials are planned, and these treatments are seen as promising due to their biologic approach and less frequent application compared to daily treatments.

Low-Level Laser Therapy (LLLT) for hair loss is effective but requires consistent use and device replacement every 1-2 years. The treatment is costly, and results may not be permanent without continued use.

User tries dermapen for hair loss and plans to use non-mainstream topicals like c60, ghk-cu, and ptd-dbm with valproic acid. They also use a head massager and modified LLLT belt for additional treatment.

Low-level laser therapy (LLLT) stimulates hair growth but current devices are expensive. A proposed non-profit project aims to create affordable, 3D-printed LLLT devices and collect data on their effectiveness.

PTD-DBM is a Korean-developed treatment for hair loss, with limited information available and some users testing it personally. A user purchased PTD-DBM for $115 and plans to test it on their temples, but its effectiveness and authenticity remain uncertain.

Pp405 is discussed as a potential hair loss treatment, with humorous suggestions about rectal administration for increased effectiveness. Users joke about unconventional methods and express willingness to try anything for hair regrowth.

Pyrilutamide, a possible hair loss treatment, ceasing to be traded due to patent laws; and the hope that this indicates it may be a legitimate treatment.

Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.

The conversation discusses hair loss treatments, specifically the effectiveness and legitimacy of low-level laser therapy (LLLT) devices under $200. The user has seen positive results with finasteride, minoxidil, ketoconazole, microneedling, and scalp massages, and seeks advice on affordable LLLT options.

Pelage is moving to Phase III clinical trials for PP405, a hair loss treatment, with results to be presented at a medical meeting. Users express skepticism and hope, comparing it to existing treatments like Minoxidil and finasteride, while discussing the potential for new hair growth in previously bald areas.

The user is considering adding low-level laser therapy (LLLT) to their hair loss treatment routine, which already includes minoxidil, finasteride, and microneedling. They are debating between purchasing a cheaper LLLT device or investing in a more expensive, clinically-backed option, with concerns about the effectiveness and specifications of cheaper models.

RU58841 from Vantanex is discussed for hair loss treatment. Users share experiences and question its legitimacy.

The conversation is about the anticipated results of Pelage's Phase 2a clinical trial for their topical hair loss treatment, PP405. Users speculate on when the results will be available, noting that delays might indicate less successful outcomes.

Pelage Pharmaceuticals is developing PP405, a topical treatment for hair growth, currently in Phase 2a trials. There is skepticism about the company's claims, and no fast-tracking approval timeline has been detailed.

A user is considering making a 2% clascoterone lotion from powder due to unavailability in their location. They plan to mix clascoterone powder with retinol lotion and use literature to determine the correct dosage.

A user is exploring VEGF gene therapy to enhance hair transplant results, considering measuring hair shaft diameter and growth rate. Suggestions include using phototrichograms and possibly adding PRP, though its effectiveness is uncertain.

Clascoterone in Winlevi, a topical AR antagonist, is being re-examined due to concerns about HPA axis suppression in adolescents, but it's unlikely to be banned for adult use in androgenetic alopecia (AGA). The European Medicines Agency recommended refusing Winlevi for acne vulgaris, but this may not affect Breezula's approval for AGA.

PP405 is not commercially available or legitimate in Europe. Users are discussing the lack of availability of this product.

A user reported positive hair growth using a regimen of oral finasteride, minoxidil, Dr. Pen, keto shampoo, and a Capillus 272 LLLT cap. Other users debated the effectiveness of the LLLT cap, with some attributing the success to the combined treatments rather than the cap alone.

The conversation is about the approval of Clascoterone (Winlevi) in Canada for hair loss treatment. One user expressed skepticism about its effectiveness due to low concentration.

The conversation is about hair loss treatments, specifically discussing the use of Minoxidil, Finasteride, and RU58841. A user inquired about the availability of Winlevi (clascoterone) for hair loss.

The user is seeking alternative hair loss treatments due to side effects from finasteride and minoxidil. They are inquiring about the availability of gt20029 from u-lab.